Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bedoradrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bedoradrine SCHEMBL7586092 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828783 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL10026405 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828780 | 1.00 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694818 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694819 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL678131 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29385851 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL1261689 | 0.98 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| SCHEMBL7585377 | 0.94 | ADRB1 (0.64) | ADRB1ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4346772-B1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4132651-B1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4702027-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20220127676-A1 | METHODS AND COMPOSITIONS FOR PROGNOSTIC AND/OR DIAGNOSTIC SUBTYPING OF PANCREATIC CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-109431965-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022046631-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | ADRB2 482/4885ADRB1 297/4885ADRB3 506/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | ADRB2 248/4885ADRB1 72/4885ADRB3 23/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | ADRB2 1416/4885ADRB1 1222/4885ADRB3 1296/4885 |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | ADRB2 4402/4885ADRB1 4437/4885ADRB3 3857/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | ADRB2 446/4885ADRB1 396/4885ADRB3 337/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | ADRB2 1235/4885ADRB1 632/4885ADRB3 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.